Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3497 Activity and safety of metformin (MET), Everolimus (EVE) and Octreotide (OCT) in patients (pts) with advanced, well-differentiated (WD) pancreatic neuroendocrine tumors (pNETs). The prospective phase II MetNET-1 trial (NCT02294006). Interim analysis

Introduction: Preclinical and clinical evidences support a role for metformin as an antineoplastic agent in WD pNETs.

Conference:

Presenting Author: Pusceddu S

Authors: Pusceddu S, Prinzi N, Corti F, Beninato T, Milione M,

Keywords: pancreatic NET, metformin, somatostatin analogues, everolimus,

#2115 Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials

Introduction: NETs are extremely heterogeneous in nature. Despite recent advances, few biomarkers are available to consistently predict prognosis and optimize treatment selection.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Chan D, Yao J, Carnaghi C, Buzzoni R, Herbst F,

Keywords: Neuroendocrine tumors, neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, everolimus, RADIANT-3, RADIANT-4, systemic inflammation, prognosis,

#2112 Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials

Introduction: Hyperglycemia and hypercholesterolemia are class effects of mTOR inhibitors such as everolimus (EVE).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F,

Keywords: adverse events, everolimus, RADIANT-3, RADIANT-4, landmark analysis, mTOR inhibitors, targeted therapy, neuroendocrine tumors,

#1218 Everolimus (EVE) for Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) from a Randomized, Double-blind, Placebo (PBO)-Controlled, Multicenter Phase 3 RADIANT-3 Study

Introduction: EVE showed a significant improvement of 6.4 mo in median progression-free survival (PFS) vs PBO (HR 0.35, 95% CI 0.27-0.45; P

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Yao J, Pavel M, Lombard-Bohas C, Van Cutsem E, Lam D,

Keywords: everolimus, pNET, OS,

#1158 A Phase II Study of Everolimus in Patients with FDG-PET Positive Intermediate Grade (Ki67 3-20%) Pancreatic Neuroendocrine Tumor

Introduction: The RADIANT-3 trial showed Everolimus (EV), as active in patients (pts) with progressive well/intermediate grade PNETs. Intermediate/grade 2 (Ki67 3-20%) PNETs have variable biology. FDG-PET avidity is an independent negative factor for survival, consistent with aggressive disease biology- but such imaging is not used to select treatment as in the case of the RADIANT 3 trial.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Michael M, Pavlakis N, Wyld D, Link E, Liauw W,

Keywords: everolimus, FDG-PET,